Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer
Authors' conclusion
Testosterone treatment of men with unequivocal hypogonadism whose organ-confined prostate cancer is treated by radical prostatectomy may be safe.
Study context
- Population
- Men aged ≥50 years with unequivocal hypogonadism (≥1 morning serum testosterone ≤220 ng/dL before prostate cancer diagnosis) and organ-confined prostate cancer treated by radical prostatectomy, who resumed testosterone within 2 years after cancer treatmentof 269 screened
- Participants
- 16 men
- Outcome
- Biochemical recurrence of prostate cancer (prostate-specific antigen ≥0.2 ng/mL)
Methodological detailselectronic medical record review, EMR search January 1, 2005, to September 20, 2021
- Electronic medical record review
- EMR search January 1, 2005, to September 20, 2021
Main finding
As reported in the abstract
Biochemical recurrence of prostate cancer · median 5 years (range, 1-20 years) of testosterone treatment and monitoring
Men with biochemical recurrence
0 of 16
Observational data: associations, not effects.
Further findings
- Baseline serum testosterone range
- 9-185 ng/dL
Original publication
Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer. Endocr Pract. Published 24 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →